|
Date:
|
Title:
|
|
11/17/05
|
Research: Actemra Monotherapy Significantly Slows Down Damage to Joints in Patients with Early Aggressive RA
Roche announced the results of the first Phase III study in rheumatoid arthritis (RA) conducted by Chugai in Japan, which were presented at the American College of Rheumatology (ACR) Annual Scientific Meeting in San Diego, USA. These data conclude for the first time that Actemra in monotherapy shows superiority to conventional disease modifying anti-rheumatic drugs (DMARDs) in inhibiting radiographic progression of joint destruction.
|
|
10/31/05
|
More than One Million Americans Helped in 6 Months by Private-Sector Drug Program
In just six months, the Partnership for Prescription Assistance (PPA), a national program dedicated to helping people in need access prescription medicines, has matched more than one million patients with assistance programs that likely meet their needs.
|
|
06/15/05
|
FDA MedWatch - COX-2 Selective and Non-Selective NSAIDs : Safety labeling changes
FDA has requested that sponsors of all non-steroidal anti-inflammatory drugs (NSAID) make labeling changes to their products.
|
|
04/27/05
|
New Drug Program Helps More Than 100,000 Patients in First Three Weeks
A new program that helps patients in need get prescription medicines is generating an outpouring of inquiries from patients nationwide.
|
|
04/20/05
|
Study Casts More Doubt on the Safety of Popular Pain Killers
With prescription drugs Vioxx and Bextra already pulled from the market, a study has raised disturbing questions about the heart safety of long-term use of over-the-counter pain relievers such as Advil, Motrin and Aleve.
|
|
04/12/05
|
Rheumatoid Arthritis Drugs Tied to Skin Problems
Dutch researchers have linked a group of rheumatoid arthritis drugs to skin problems. Humira (adalimumab), Remicade (infliximab), and Enbrel (etanercept) are mentioned in the study, which appears in the journal Arthritis Research and Therapy.
|
|
04/07/05
|
FDA Asks Pfizer to Voluntarily Remove Bextra ( valdecoxib) From the Market
After concluding that the overall risk versus benefit profile is unfavorable, FDA has requested Pfizer to voluntarily withdraw Bextra (valdecoxib) from the market.
|
|
03/31/05
|
First Head-to-Head Study to Compare Lidoderm Patch and Celebrex in Treating Pain
Study results suggest that lidoderm can alleviate the pain associated with osteoarthritis of the knee.
|
|
01/31/05
|
Kaiser Orders Ban on Arthritis Drug Bextra
Oakland-based Kaiser Permanente has ordered its pharmacies to stop dispensing Bextra, a painkiller that some tests have shown increased the risk of heart attack, a spokeswoman said Saturday.
|
|
01/06/05
|
FDA Approves Pfizer’s LyricaTM for the Treatment of the Two Most Common Forms of Neuropathic (Nerve) Pain
NEW YORK, December 31, 2004 -- Pfizer Inc said today that it has received approval from the U.S. Food and Drug Administration (FDA) to market LyricaTM (pregabalin capsules) for the management of neuropathic pain associated with diabetic peripheral neuropathy (DPN) and postherpetic neuralgia (PHN).
|
